Clin2
NCT06854640Possibly a fitRecruiting

A study of a new medicine for sepsis-related blood clotting problems

SepsisCoagulopathy

Part of Blood & lymphatic, Heart & circulation, Infections clinical trials.

This study tests a new medicine called BAY 3389934 to see if it's safe and what dose works best for people with sepsis and blood clotting issues. The goal is to improve blood clotting and help you recover from the infection.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
36 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You must be between 18 and 85 years old.
  • You must have sepsis, which is a serious infection that causes organ problems.
  • You must have a blood clotting problem due to sepsis, like low platelets or increased clotting time.
  • You must be in an intensive care unit (ICU) for treatment.
  • You must not have active bleeding or a bleeding disorder.
  • You must not have had major surgery or injury recently, and you must not be taking certain blood-thinning medications (except low-dose aspirin).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07214103Not yet recruiting· Phase 2
Sivelestat for septic shock with clotting problems

This trial tests a drug called sivelestat to see if it can help people with severe infections who also have blood clotting problems. The drug may reduce the risk of organ damage and improve recovery.

Strasbourg, France
NCT07160426Not yet recruiting· Phase 2
Study of a treatment for severe infections (sepsis)

This trial tests a new treatment to protect and repair the layer of cells lining your blood vessels (glycocalyx) during sepsis. It aims to improve recovery from severe infections.

NCT06078839Not yet recruiting· Phase 4
Drug for blood clotting problems in severe infections

This trial tests an experimental drug called nafamostat mesilate to help control blood clotting problems in people with severe infections (sepsis). It aims to reduce the risk of abnormal blood clots that can harm organs.

NCT07353970Not yet recruiting
Severe infection and sepsis study

This study looks at how certain natural molecules in your blood might affect recovery from severe infections or sepsis. By understanding these molecules, doctors hope to better predict outcomes and personalize treatment for patients in the ICU.

NCT07595133Not yet recruiting· Phase 1
Study of romiplostim for low platelets from sepsis

This trial tests a drug called romiplostim to see if it can safely raise platelet counts in people with sepsis (a severe infection that can cause organ damage). If you have low platelets due to sepsis, this treatment might help reduce bleeding risks.

NCT05634057Recruiting
Treating sepsis with a medication plus blood thinner

This trial studies whether combining anisodamine (a medicine for certain gut/smooth-muscle effects) with a low-molecular-weight blood thinner helps treat sepsis. It may be aimed at improving outcomes compared with standard care, but eligibility depends on safety factors like bleeding risk and organ function.

Beijing, China

Hear when a new Sepsis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.